← boardnext 2027-10next 2027-12next 2028-01next 2028-08next 2031-06-30
OPK
OPKO Health, Inc.distress 0/10 · well-funded / low risk$1.180%today-25% from 52w high
Lead: Advanced Tumors
Revenue
$124M
Liquidity
$342M
Runway
2.1 yrs
Shares 1y
-2%
Price & events
-13.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.8%
1W
-19.2%
1M
-3.3%
3M
-10.6%
6M
-17.5%
1Y
-18.1%
2Y
-67.6%
5Y
-71.9%
All
Overview
- Market Cap
- $891.01M
- Enterprise Value
- $561.15M
- Volume
- 257.03K
- 52 Week Range
- $1.10 – $1.58
- Total Shares
- 755.09M
- Float Shares
- 332.82M
- Short %
- 7.70%
- % Held by Insiders
- 49.95%
- % Held by Institutions
- 27.02%
- RVOL
- 0.09x
- Beta
- 1.48
Pipeline stages · 5 programs
CTAP101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
OPK-88006
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MDX2003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MDX2001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MDX2004
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | CTAP101 | CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | OPK-88006 | MASH | — | not yet recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 1/2 | MDX2003 | Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL, HGBCL, FL Lymphoma, Lymphoplasmacytic Lymphoma, Follicular Lymphoma (FL) | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 1/2 | MDX2001 | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer | — | recruiting |
| 2031-06-30 Estimated 50% readout ~2031-08-14 | Phase 1/2 | MDX2004 | Advanced Tumors | — | recruiting |
Catalyst news & presentations · 3
- 2026-07-30earningsEarningsEarnings releaseyahoo
- 2025-09-15partnershipOPKO completed sale of select oncology testing assets to Labcorp for up to $225M including $192.5M at closing and up to $32.5M earnout.SEC 8-K
- 2025-03-10partnershipAsset Purchase Agreement to sell oncology lab testing business to LabCorpSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $4 (+271% upside) · 4 analysts
- 2026-04-29Barrington ResearchOutperform → Market Perform
- 2026-03-02Barrington ResearchOutperform
- 2025-11-20JP MorganNeutral
- 2025-10-31JefferiesBuy → Hold
- 2025-10-30Barrington ResearchOutperform
- 2025-05-01Barrington ResearchOutperform
Competitors — Advanced Tumors
- none identified
Recent news
- 2026-07-23OPKO Health (OPK) Projected to Announce Earnings on Thursday - MarketBeat
- 2026-07-22OPKO Health stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
- 2026-07-20OPKO Health, Inc. (NASDAQ:OPK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
- 2026-07-13Zacks Research Has Weak Estimate for OPKO Health Q2 Earnings - MarketBeat
- 2026-07-03OPKO Health Inc focuses on diagnostics and pharmaceuticals as investors weigh long-term prospects - Ad-hoc-news.de
- 2026-07-03OPKO Health (OPK) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
- 2026-06-25OPK Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-22OPKO Health (OPK) director receives 30,000-share stock option award at $1.42 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.